| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Discontinuation Study | 20-28 | Multiple Myeloma in sustainable |
DSSG Group: Multiple Myeloma
CA057-001
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| CA057-001 | CA057-001 | Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. |
|
CA058-1019
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA058-1019 | CA058-1019 | Relapsed or refractory multiple myeloma who have already had 2 to 3 lines of MM therapy, including a drug called lenalidomide and a drug from a class called anti-CD38 antibodies. |
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM). |
MajesTEC-4
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MajesTEC-4 | 23-21 | Newly diagnosed multiple myeloma |
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant. |
AFFIRM-AL
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Isa-RVD
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Isa-RVD | 19-34 | The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria. |
This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma |